TriangleNCT01282424 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Start of Treatment to Last Long-Term Follow-Up Visit (up to maximum of 7 years)
What was measured
Overall survival (OS) was defined as the time interval from the start of idelalisib treatment to death from any cause. OS was analyzed using KM estimates.
Analysis population: Participants in the ITT Analysis Set were analyzed.
Groups in this outcome
Idelalisib
Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.
| Group | Source count |
|---|---|
| Idelalisib | 125 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Idelalisib | 48.6 | Not reported | 33.9 | 71.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 33.9
- upper Limit
- 71.7
- value
- 48.6
- denoms
- counts
- group Id
- OG000
- value
- 125
- units
- Participants
- description
- Overall survival (OS) was defined as the time interval from the start of idelalisib treatment to death from any cause. OS was analyzed using KM estimates.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.
- id
- OG000
- title
- Idelalisib
- param Type
- MEDIAN
- population Description
- Participants in the ITT Analysis Set were analyzed.
- reporting Status
- POSTED
- time Frame
- Start of Treatment to Last Long-Term Follow-Up Visit (up to maximum of 7 years)
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice